LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Regeneron Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

628.61 1.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

618.69

Massimo

631.75

Metriche Chiave

By Trading Economics

Entrata

-117M

727M

Vendite

-279M

3.6B

P/E

Media del settore

14.661

49.888

EPS

9.47

Rendimento da dividendi

0.58

Margine di Profitto

20.17

Dipendenti

15,343

EBITDA

-234M

967M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+34.06% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.58%

2.38%

Utili prossimi

31 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-15B

63B

Apertura precedente

627

Chiusura precedente

628.61

Notizie sul Sentiment di mercato

By Acuity

41%

59%

132 / 344 Classifica in Healthcare

Regeneron Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 ago 2025, 11:33 UTC

Utili

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 apr 2026, 12:01 UTC

Utili

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 apr 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mar 2026, 11:02 UTC

Discorsi di Mercato

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dic 2025, 08:30 UTC

Acquisizioni, Fusioni, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 ago 2025, 13:16 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 10:41 UTC

Utili

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 ago 2025, 10:41 UTC

Utili

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 ago 2025, 10:40 UTC

Utili

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 ago 2025, 10:38 UTC

Utili

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 ago 2025, 10:37 UTC

Utili

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 ago 2025, 10:35 UTC

Utili

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 ago 2025, 10:34 UTC

Utili

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 ago 2025, 10:33 UTC

Utili

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 ago 2025, 10:32 UTC

Utili

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 ago 2025, 10:31 UTC

Utili

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 ago 2025, 10:31 UTC

Utili

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Rev $3.68B >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q EPS $12.81 >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Net $1.39B >REGN

13 giu 2025, 21:42 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 giu 2025, 20:45 UTC

Acquisizioni, Fusioni, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 giu 2025, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

Confronto tra pari

Modifica del prezzo

Regeneron Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.06% in crescita

Previsioni per 12 mesi

Media 829.77 USD  34.06%

Alto 995 USD

Basso 641 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

22 ratings

16

Acquista

6

Mantieni

0

Vendi

Sentiment

By Acuity

132 / 344 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat